WEB-LIVESTREAMING AOCMF 2nd ARONJ Conference, Munich
Munich, Germany
17 Sep 2018
Download vCalendar file
Quick access
Description
It is our pleasure to announce the Web-Livestreaming of AOCMF's second conference on ARONJ ('Anti-osteoclastic drugs and their impact on maxillofacial and orthopedic bone biology, surgery, disease, and treatment'), taking place in Munich. The conference brings together experts and leading principal investigators of AOCMF ARONJ projects who will share their updated results and encourage debate and discussion on the topic. In case you will not be able to participate in person in Munich, don't miss the opportunity to attend via WEB and LIVE. Register now.

This conference is aiming for specialists active in the (non-)surgical management of patients with ARONJ/BRONJ disease. A personalized login-link will be provided shortly prior the start of the conference.
Contributors
Eppo Wolvius  (Course Chair)
View all
View conflicts of interest
Details
ID ARONJLIVE2018
Type AOCMF
Level Principles
Region Europe and Southern Africa
Language(s) English
Scope International
Academic status Non peer reviewed
Format Symposium
Content Debates, Lectures
Target audience Clinical investigations, CMF musculoskeletal oncology, ENT surgery, General surgery, Neurosurgery, Oral and maxillofacial surgery, Other, Plastic surgery, Research, Residency
Registration
Registration start19 Jul 2018
Closing date17 Sep 2018
Statusclosed
Places200
Available places19
Cancellation policyNo refund for cancellations
Pricing
Euro 40.00 EUR
Payment options and information
Members: Free of charge
Non-members: EUR 40.00, payment is by credit card

Background to AOCMF ARONJ Clinical Priority Program (CPP)
Bisphosphonates (Alendronate, Zolendronate, Pamidronate and others) and additional anti-osteoclastic drugs such as RANKL inhibitors (Denosumab) are among the most prescribed drugs in the world today. 26 million prescriptions for Alendronate in the US alone are used for treatment of postmenopausal osteoporosis and 250,000 patients with metastatic bone cancer are treated with high dose intravenous bisphosphonates. These drugs have been noted to have profound influences on oral and orthopedic health including exacerbation of dental diseases, osteonecrosis of the jaw requiring ablation, spiral fractures of the femur, bone pain, and spinal and other foramenal stenosis, are some of the areas of impact associated with anti-osteoclastic drugs. These medications have also been associated with a marked decrease in femoral neck fractures, compression fractures of the spine and other osteoporotic fractures such as wrist and humerus.

AOCMF launched a CPP program sponsoring diverse research projects to investigate on the field of ARONJ and is excited to share further results after a very successful first AOCMF ARONJ Conference in 2016, in London.


Contact(s)
Ms Mirjam Bucher (Faculty & Participant Contact)
AO Foundation, AOCMF
AOCMF R&D Senior Project Manager, AOCMF R&D Senior Fellowship Manager
Stettbachstr. 6
8600 Dübendorf
Switzerland
Phone+41442002470
Mobile+41794401339
Emailmirjam.bucher@aofoundation.org
Ms Raluca Herren (Faculty & Participant Contact)
AOCMF
Communications Specialist
Clavadelerstrasse 8
7270 Davos
Switzerland
Phone+41794167160
Mobile+41794167160
Emailraluca.herren@aocmf.org
Venue
via personalized login link